文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

人绒毛膜促性腺激素衍生物EA-230在心脏手术患者中的安全性与有效性:随机双盲安慰剂对照研究

Safety and Efficacy of Human Chorionic Gonadotropin Hormone-Derivative EA-230 in Cardiac Surgery Patients: A Randomized Double-Blind Placebo-Controlled Study.
PubMed 文献 · Crit Care Med · 2021-01-01
一句话结论EA-230在体外循环心脏手术患者中安全,虽未调节白细胞介素-6,但似乎有肾脏和心血管获益并缩短住院时间。

该研究为双盲、安慰剂对照、随机研究,纳入180例接受体外循环冠状动脉旁路移植术(伴或不伴瓣膜手术)的患者,术中给予90 mg/kg/hr EA-230或安慰剂。EA-230未调节白细胞介素-6血浆浓度(曲线下面积2730 pg/mL×hr vs 2680 pg/mL×hr,p=0.80)。术后肾小球滤过率增加,EA-230组较安慰剂组使用碘海醇血浆清除率测定的肾小球滤过率增加19±2 vs 16±2 mL/min/1.73 m2(p=0.13),使用肌酐的肾脏病饮食改良方程估算的肾小球滤过率增加6±1 vs 2±1 mL/min/1.73 m2(p=0.01)。EA-230组急性肾损伤RIFLE标准「损伤」期发生率为7% vs 安慰剂组18%(p=0.07);液体正平衡更少(217±108 vs 605±103 mL,p=0.01),血管活性药物使用相似(p=0.39),住院时间更短(8天[7-11] vs 10天[8-12],p=0.001)。作者认为EA-230安全,似乎发挥有益的肾脏和心血管效应并缩短住院时间。

要点

  • 180例体外循环冠脉搭桥(±瓣膜手术)患者术中接受EA-230 90 mg/kg/hr或安慰剂,未出现安全性担忧。
  • EA-230未调节白细胞介素-6:曲线下面积2730 pg/mL×hr vs 2680 pg/mL×hr,p=0.80。
  • 估算肾小球滤过率增加EA-230组6±1 vs 安慰剂组2±1 mL/min/1.73 m2(p=0.01);碘海醇测定的肾小球滤过率增加19±2 vs 16±2 mL/min/1.73 m2(p=0.13)。
  • 急性肾损伤RIFLE「损伤」期EA-230组7% vs 安慰剂组18%(p=0.07);液体正平衡217±108 vs 605±103 mL(p=0.01)。
  • 住院时间EA-230组8天[7-11] vs 安慰剂组10天[8-12](p=0.001);手术和药物输注时间更长的患者疗效结果更明显。

适用人群与场景

  • 接受体外循环冠状动脉旁路移植术伴或不伴同期瓣膜手术的患者180例。
  • 研究在荷兰一家三级医院的心胸外科、麻醉科和重症监护科协作开展。

诊断标准与关键阈值

  • 急性肾损伤采用RIFLE标准(风险、损伤、衰竭、肾功能丧失和终末期肾病)分期。

处置流程与药物剂量

  • 术中给予EA-230 90 mg/kg/hr或安慰剂。
  • 研究期间未出现安全性担忧。

研究设计与关键结果

  • 研究设计:双盲、安慰剂对照、随机研究;样本量180例;人群为接受体外循环冠状动脉旁路移植术伴或不伴同期瓣膜手术的患者;干预为术中EA-230 90 mg/kg/hr,对照为安慰剂。
  • 主要炎症终点:EA-230未调节白细胞介素-6血浆浓度,曲线下面积EA-230组2730 pg/mL×hr(1968-3760)vs 安慰剂组2680 pg/mL×hr(2090-3570),p=0.80。
  • 肾功能:碘海醇血浆清除率测定的肾小球滤过率术后增加,EA-230组19±2 vs 安慰剂组16±2 mL/min/1.73 m2,p=0.13;使用肌酐的肾脏病饮食改良方程估算的肾小球滤过率增加,EA-230组6±1 vs 安慰剂组2±1 mL/min/1.73 m2,p=0.01。
  • 急性肾损伤RIFLE「损伤」期发生率EA-230组7% vs 安慰剂组18%,p=0.07。
  • 液体平衡:EA-230组液体正平衡217±108 mL vs 安慰剂组605±103 mL,p=0.01。
  • 血管活性药物使用两组相似,p=0.39。
  • 住院时间:EA-230组8天(7-11)vs 安慰剂组10天(8-12),p=0.001。
  • 疗效结果在手术时间更长、因而研究药物输注时间更长的患者中更明显。

证据类型、等级与局限

  • 证据类型:随机双盲安慰剂对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为EA-230在体外循环心脏手术患者中安全,未调节白细胞介素-6血浆浓度,但似乎发挥有益的肾脏和心血管效应并缩短住院时间。
  • 疗效结果在手术时间更长、研究药物输注时间更长的患者中更明显。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine the safety and efficacy of human chorionic gonadotropin hormone-derivative EA-230 in cardiac surgery patients. Cardiac surgery induces systemic inflammation and may impair renal function, affecting patient outcome. EA-230 exerted immunomodulatory and renoprotective effects in preclinical models and was safe and showed efficacy in phase I and II human studies.

DESIGN: Double-blinded, placebo-controlled, randomized study.

SETTING: Collaboration of the Cardiothoracic Surgery, Anesthesiology, and the Intensive Care departments of a tertiary hospital in the Netherlands.

PATIENTS: One hundred eighty patients undergoing an on-pump coronary artery bypass procedure with or without concomitant valve surgery.

INTERVENTIONS: Ninety mg/kg/hr EA-230 or placebo administered during surgery.

MEASUREMENTS AND MAIN RESULTS: During the study, no safety concerns emerged. EA-230 did not modulate interleukin-6 plasma concentrations (area under the curve 2,730 pg/mL × hr [1,968-3,760] vs 2,680 pg/mL × hr [2,090-3,570] for EA-230 and placebo group, respectively; p = 0.80). Glomerular filtration rate increased following surgery (mean ± sem increase in the EA-230 vs placebo groups: glomerular filtration rateiohexol measured using iohexol plasma clearance: 19 ± 2 vs 16 ± 2 mL/min/1.73 m2; p = 0.13 and estimated glomerular filtration rate with the Modification of Diet in Renal Disease equation using creatinine: 6 ± 1 vs 2 ± 1 mL/min/1.73 m2; p = 0.01). The "injury" stage of the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease criteria for acute kidney injury was 7% in the EA-230 group versus 18% in the placebo group (p = 0.07). In addition, EA-230-treated patients had a less positive fluid balance compared with placebo-treated patients (217 ± 108 vs 605 ± 103 mL; p = 0.01), while the use of vasoactive agents was similar in both groups (p = 0.39). Finally, hospital length of stay was shorter in EA-230 treated patients (8 d [7-11] vs 10 d [8-12]; p = 0.001). Efficacy results were more pronounced in patients that had longer duration of surgery and thus longer duration of study drug infusion.

CONCLUSIONS: EA-230 was safe in patients undergoing on-pump cardiac surgery. It did not modulate interleukin-6 plasma concentrations but appeared to exert beneficial renal and cardiovascular effects and shortened in-hospital length of stay.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. van Groenendael R, Beunders R, Hemelaar P, et al. Safety and Efficacy of Human Chorionic Gonadotropin Hormone-Derivative EA-230 in Cardiac Surgery Patients: A Randomized Double-Blind Placebo-Controlled Study. Crit Care Med. 2021. PMID: 33591006. doi:10.1097/CCM.0000000000004847

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。